CliffBio
small molecule

AMBELVIST

GADOQUATRANE

Loss of exclusivityMay 2040latest FDA-listed patent expiry
CompanyBAYER HEALTHCARE PHARMACEUTICALS INC

Drug detail

Brand nameAMBELVIST
Active ingredientGADOQUATRANE
Strength0.5158GM/2ML (257.9MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 2026
Marketing statusRX

Listed patents

PatentExpiresType
11944690May 2040product
12303573November 2039product
10722601May 2036substance
10137209May 2036substance
12478696May 2036substance
11491245May 2036substance

Regulatory exclusivity

CodeExpires
NCEJune 2031

More from BAYER HEALTHCARE PHARMACEUTICALS INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.